Suppr超能文献

圣约翰草与低剂量口服避孕药疗法的相互作用:一项随机对照试验。

Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.

作者信息

Pfrunder Arabelle, Schiesser Monika, Gerber Simone, Haschke Manuel, Bitzer Johannes, Drewe Juergen

机构信息

Department of Clinical Pharmacology and Toxicology, Women's Hospital, University Clinic Basel/Kantonsspital, Basel, Switzerland.

出版信息

Br J Clin Pharmacol. 2003 Dec;56(6):683-90. doi: 10.1046/j.1365-2125.2003.02005.x.

Abstract

AIMS

Breakthrough bleeding or even unwanted pregnancies have been reported in women during concomitant therapy with oral contraceptives and St John's wort extract. The aim of the present study was to investigate the effects of St John's wort extract on oral contraceptive therapy with respect to ovarian activity, breakthrough bleeding episodes and the pharmacokinetics of ethinyloestradiol and 3-ketodesogestrel.

METHODS

Eighteen healthy females were treated with a low-dose oral contraceptive (0.02 mg ethinyloestradiol, 0.150 mg desogestrel) alone (control cycle) or combined with 300 mg St John's wort extract given twice daily (cycle A) or three times daily (cycle B). Ovarian activity was assessed by measuring follicle maturation and serum oestradiol and progesterone concentrations. The number of breakthrough bleeding episodes and the pharmacokinetics of ethinyloestradiol and 3-ketodesogestrel were assessed under steady-state conditions.

RESULTS

During concomitant administration of low-dose oral contraceptive and St John's wort, there was no significant change in follicle maturation, serum oestradiol or progesterone concentrations when compared with oral contraceptive treatment alone. However, significantly more subjects reported intracyclic bleeding during cycles A (13/17 (77%), P < 0.015) and cycle B (15/17 (88%), P < 0.001) than with oral contraceptives alone (6/17 (35%)). The AUC(0,24 h) and Cmax of ethinyloestradiol remained unchanged during all study cycles, whereas the AUC(0,24 h) and Cmax of 3-ketodesogestrel decreased significantly from 31.2 ng ml-1 h to 17.7 ng x ml-1 h (43.9%; 95% confidence interval (CI) -49.3, -38.5, P = 0.001) and from 3.6 ng x ml -1 to 3.0 ng x ml -1(17.8%; CI -29.9, -5.7, P = 0.005), respectively, during cycle A and by 41.7% (CI -47.9, -35.6; P = 0.001) and by 22.8% (CI -31.2, -13.3; P < 0.001) during cycle B respectively, compared with the control cycle.

CONCLUSIONS

There was no evidence of ovulation during low-dose oral contraceptive and St John's wort extract combination therapy, but intracyclic bleeding episodes increased. Bleeding irregularities may adversely effect compliance to oral contraceptives and together with St John's wort-induced decreases in serum 3-ketodesogestrel concentrations, enhance the risk of unintended pregnancies.

摘要

目的

有报道称女性在口服避孕药与圣约翰草提取物联合治疗期间出现突破性出血甚至意外怀孕。本研究的目的是调查圣约翰草提取物对口服避孕药治疗在卵巢活性、突破性出血发作以及乙炔雌二醇和3 - 酮去氧孕烯的药代动力学方面的影响。

方法

18名健康女性接受低剂量口服避孕药(0.02mg乙炔雌二醇,0.150mg去氧孕烯)单独治疗(对照周期),或联合每日两次(周期A)或每日三次(周期B)给予300mg圣约翰草提取物。通过测量卵泡成熟度以及血清雌二醇和孕酮浓度来评估卵巢活性。在稳态条件下评估突破性出血发作次数以及乙炔雌二醇和3 - 酮去氧孕烯的药代动力学。

结果

在低剂量口服避孕药与圣约翰草联合给药期间,与单独口服避孕药治疗相比,卵泡成熟度、血清雌二醇或孕酮浓度没有显著变化。然而,与单独口服避孕药(6/17(35%))相比,在周期A(13/17(77%),P < 0.015)和周期B(15/17(88%),P < 0.001)期间报告有周期内出血的受试者明显更多。在所有研究周期中,乙炔雌二醇的AUC(0,24 h)和Cmax保持不变,而3 - 酮去氧孕烯的AUC(0,24 h)和Cmax在周期A中分别从31.2 ng·ml⁻¹·h显著降至17.7 ng·ml⁻¹·h(43.9%;95%置信区间(CI)-49.3,-38.5,P = 0.001)和从3.6 ng·ml⁻¹降至3.0 ng·ml⁻¹(17.8%;CI -29.9,-5.7,P = 0.005),在周期B中分别下降41.7%(CI -47.9,-35.6;P = 0.001)和22.8%(CI -31.2,-13.3;P < 0.001),与对照周期相比。

结论

在低剂量口服避孕药与圣约翰草提取物联合治疗期间没有排卵证据,但周期内出血发作增加。出血不规律可能对口服避孕药的依从性产生不利影响,并且与圣约翰草引起的血清3 - 酮去氧孕烯浓度降低一起,增加意外怀孕的风险。

相似文献

1
Interaction of St John's wort with low-dose oral contraceptive therapy: a randomized controlled trial.
Br J Clin Pharmacol. 2003 Dec;56(6):683-90. doi: 10.1046/j.1365-2125.2003.02005.x.
3
The interaction between St John's wort and an oral contraceptive.
Clin Pharmacol Ther. 2003 Dec;74(6):525-35. doi: 10.1016/j.clpt.2003.08.009.
4
St John's wort extract (Ze 117) does not alter the pharmacokinetics of a low-dose oral contraceptive.
Eur J Clin Pharmacol. 2009 Mar;65(3):287-94. doi: 10.1007/s00228-008-0587-2. Epub 2008 Nov 18.
5
Effect of St John's wort on imatinib mesylate pharmacokinetics.
Clin Pharmacol Ther. 2004 Oct;76(4):323-9. doi: 10.1016/j.clpt.2004.06.007.
8
Different effects of St John's wort on the pharmacokinetics of simvastatin and pravastatin.
Clin Pharmacol Ther. 2001 Dec;70(6):518-24. doi: 10.1067/mcp.2001.120025.
9
Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
Br J Clin Pharmacol. 2004 May;57(5):592-9. doi: 10.1111/j.1365-2125.2003.02051.x.
10
Lack of effect of St John's Wort on carbamazepine pharmacokinetics in healthy volunteers.
Clin Pharmacol Ther. 2000 Dec;68(6):605-12. doi: 10.1067/mcp.2000.111530.

引用本文的文献

1
Clinical relevance of St. John's wort drug interactions revisited.
Br J Pharmacol. 2020 Mar;177(6):1212-1226. doi: 10.1111/bph.14936. Epub 2020 Jan 17.
2
PXR as a mediator of herb-drug interaction.
J Food Drug Anal. 2018 Apr;26(2S):S26-S31. doi: 10.1016/j.jfda.2017.11.007. Epub 2017 Dec 19.
4
Neuroprotective Activity of Hypericum perforatum and Its Major Components.
Front Plant Sci. 2016 Jul 11;7:1004. doi: 10.3389/fpls.2016.01004. eCollection 2016.
5
Co-administration of St. John's wort and hormonal contraceptives: a systematic review.
Contraception. 2016 Dec;94(6):668-677. doi: 10.1016/j.contraception.2016.07.010. Epub 2016 Jul 18.
6
Cytochrome P450 enzyme mediated herbal drug interactions (Part 1).
EXCLI J. 2014 Apr 2;13:347-91. eCollection 2014.
8
A survey describing the use of complementary therapies and medicines by women attending a family planning clinic.
BMC Complement Altern Med. 2013 Sep 11;13:224. doi: 10.1186/1472-6882-13-224.
10
Drug interactions with herbal medicines.
Clin Pharmacokinet. 2012 Feb 1;51(2):77-104. doi: 10.2165/11597910-000000000-00000.

本文引用的文献

1
Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception.
Br J Clin Pharmacol. 2003 Jan;55(1):112-3. doi: 10.1046/j.1365-2125.2003.01716.x.
2
St John's wort (Hypericum perforatum): drug interactions and clinical outcomes.
Br J Clin Pharmacol. 2002 Oct;54(4):349-56. doi: 10.1046/j.1365-2125.2002.01683.x.
3
St John's wort and depression.
JAMA. 2002;288(4):447-8; author reply 448-9.
4
St Johns wort increases expression of P-glycoprotein: implications for drug interactions.
Br J Clin Pharmacol. 2002 Jan;53(1):75-82. doi: 10.1046/j.0306-5251.2001.01516.x.
5
Saint John's wort: an in vitro analysis of P-glycoprotein induction due to extended exposure.
Br J Pharmacol. 2001 Dec;134(8):1601-8. doi: 10.1038/sj.bjp.0704399.
8
St John's Wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4.
Clin Pharmacol Ther. 2000 Dec;68(6):598-604. doi: 10.1067/mcp.2000.112240.
10
Drug interaction between St. John's wort and cyclosporine.
Ann Pharmacother. 2000 Sep;34(9):1013-6. doi: 10.1345/aph.10088.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验